Skip to main content

Table 3 Percentage increase in antibody titers 28 days post vaccination

From: Response to influenza vaccination in immunocompromised children with rheumatic disease: a prospective cohort study

 

All patients

(n = 226)

(missinga: 24/28)

bDMARDs monotherapy

(n = 80)

(missinga: 8/14)

bDMARDs + DMARDs

(n = 110)

(missinga: 13/11)

Rituximab

(n = 5)

(missinga: 1/0)

Systemic disorders

(n = 18)

(missinga: 1/1)

Other

(n = 13)

(missinga: 1/2)

Controls

(n = 15)

(missinga: 4/2)

A/Cal H1N1pdm09

62.7 (31.9–100.6)

44.9 (9.2–92.4)

82.2 (43.4–131.4)

2.2 (-45.6–129.2)

30.8 (-83.9–104.0)

108.2 (23.6–250.6)

74.2 (4.9–189.3)

A/Swi H3N2

74.9 (48.3–106.3)

89.9 (51.8–137.6)

64.3 (36.1–98.5)

63.3 (-86.9–206.9)

96.2 (38.5–177.9)

77.1 (17.7–166.5)

193.2 (96.8–336.5)

B/Phu Yamagata

12.3 (-98.3–28.4)

5.1 (-87.9–25.7)

6.7 (-91.8–23.9)

71.8 (5.1–180.9)

20.2 (-91.5–57.9)

37.2 (-99.6–88.9)

53.9 (12.5–110.5)

  1. Abbreviations: DMARDs disease modifying antirheumatic drugs; bDMARD biological DMARDs
  2. Data are % (95 % CI). a Numbers missing pre-vaccine and post-vaccine, respectively
  3. A linear mixed model was used to estimate the increases from pre-vaccine to post-vaccine adjusted for the number of days between vaccination and post vaccination blood sampling. Percentage increase is reported at day 28 post vaccination
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096